Files
Abstract
Neuroinflammation and mitochondrial dysfunction are early events in Alzheimer’s disease (AD) and contribute to neurodegeneration and cognitive impairment. The CD74-MIF (macrophage migration inhibitory factor) axis is a mediator of the neuroinflammatory response. DRhQ competitively inhibits MIF-CD74 binding and elicits beneficial effects in other neurodegenerative disease models. Here we evaluate its effects in β-amyloid (Aβ) overexpressing mice.